Moderna Inc MRNA

$190.01 +1.07 (0.57%)

Valuation

Market cap
75,858,832,000
Revenue TTM
$1,944,000,000
Net income TTM
$-2,822,000,000
PE ratio
0.00
Forward PE
—
Profit margin
-145.16%
Debt to equity
0.09

Trading

Volume
10,289,400
Avg volume
20,080,861
Day's range
$183.28 – $193.72
Shares out
399,236,000
Stochastic %K
53%
Beta
1.09
Analysts
Sell
Price target
$123.00

Price

Company profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public...

Show more

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 714 6500
Website
https://www.modernatx.com
Address
325 Binney Street, Cambridge, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 4, 8:17 PM
$SLS $MRNA "Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe Sellas is on the verge of such an advance. I have been impressed with the significant potential of the companies lead product Galinpepimut-s to successfully treat hematological and solid malignancy through a unique approach of peptide based immunization against the WT1 Onco protein stated Dr. Weber • 50,000 AML Remission Patients will be treated with Gps Immunotherapy each year - Phase 3 MOS is right now at least 34 months for CR2/3 Patients and SOC/BAT MOS for CR1 patients is only 24.7 . . . SLS is about to add $20B to $40B to its Mcap -- the instant P3 Results are announced.
0 replies
55X_ROI_Q1_2026 Oct 4, 7:48 PM
$SLS $MRNA Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe Sellas is on the verge of such an advance. I have been impressed with the significant potential of the companies lead product Galinpepimut-s to successfully treat hematological and solid malignancy through a unique approach of peptide based immunization against the WT1 Onco protein stated Dr. Weber
0 replies
55X_ROI_Q1_2026 Oct 4, 7:17 PM
$SLS Interesting to read what Dr. Weber, who developed Opdivo and $MRNA -4157, said about GPS $SLS at the Gps Phase 3 Outset, esp considering the Gps PH3 Registrational Results are Now Truly Imminent. "Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe Sellas is on the verge of such an advance. I have been impressed with the significant potential of the companies lead product Galinpepimut-s to successfully treat hematological and solid malignancy through a unique approach of peptide based immunization against the WT1 Onco protein stated Dr. Weber Dr. Jeff Weber... continued to lead the field of novel immune oncology approaches, particularly surrounding neoantigen vaccine development in melanoma. He designed and led the phase II trial of pembrolizumab, with or without the individualised neoantigen therapy mRNA-4157/V940 $MRNA . https://pmc.ncbi.nlm.nih.gov/articles/PMC11409376/ • 78th event occurred 146 days ago - had been seeing 1 event /month.
0 replies
TradeWithInsight Oct 4, 6:59 PM
$MRNA is the setup from last week's list worth studying. The plan was over 202.67, target 210.96, stop 197.44. Tuesday's open triggered it and the first half hour ran to 208.90, about 2 short of target, then it reversed and took the 197.44 stop before 10:30 AM ET. It closed Tuesday at 203.46, back above the trigger, which stings. Wednesday it opened at 186.55, about 11 points below the stop. A stop hit on noise feels like a mistake until the next open shows what holding would have cost.
0 replies
Batman9988 Oct 4, 5:36 PM
$QQQ $NVAX $MRNA $GOVX So we pumping vaccine stocks on Monday 🤦🤷 https://people.com/woman-dies-of-suspected-plague-in-russia-nearly-200-people-placed-under-medical-observation-12156861
1 replies
SupremeSwinger Oct 4, 5:18 PM
$NBIS 235C 150% $750 gains $MRNA 180C 280% $990 gains $META 727.5C 100% $2600 gains $NBIS 225C 100% $1300 gains
0 replies
SupremeSwinger Oct 4, 5:07 PM
$MRNA 180C 420% $1400 gains $OUST 39C 360% $320 gains $BE 267.5C 260% $1700 $SKHY 187.5C 100% $200
0 replies
SupremeSwinger Oct 4, 4:54 PM
$AMD 602.5C 220% 607.5C 400% $MRNA 200P 180% $META 732.5P 120%
0 replies